Search

Your search keyword '"Bittencourt, Henrique"' showing total 716 results
Start Over Author "Bittencourt, Henrique"
716 results on '"Bittencourt, Henrique"'

201. Outcomes after Double Umbilical Cord Blood Transplantation in Children: A Survey on Behalf of Eurocord and PDWP-EBMT

Author

Giannotti, Federica, primary, Ruggeri, Annalisa, additional, Michel, Gerard, additional, Dalle, Jean-Hugues, additional, O'Brien, Tracey, additional, Al-Seraihy, Amal, additional, Hough, Rachael, additional, Rohrlich, Pierre-Simon, additional, Jubert, Charlotte, additional, Bittencourt, Henrique, additional, Gandemer, Virginie, additional, Chastagner, Pascal, additional, Skorobogatova, Elena, additional, Sirvent, Anne, additional, Rialland, Fanny, additional, Lawson, Sarah, additional, Lioure, Bruno, additional, Veys, Paul, additional, Shaw, Peter J., additional, Passweg, Jakob, additional, Shekhovtsova, Zhanna, additional, Volt, Fernanda, additional, Peters, Christina, additional, Bader, Peter, additional, Gluckman, Eliane, additional, and Rocha, Vanderson, additional

Published
2014
Full Text
View/download PDF

202. Calcineurin Inhibitor-free Graft-Versus-Host Disease Prophylaxis With Sirolimus and Mycophenolate Mofetil in a Second Allogeneic Stem Cell Transplantation for Engraftment Failure and Rituximab-refractory Epstein-Barr Virus–induced Posttransplant Lymphoproliferative Disease

Author

Ceppi, Francesco, primary, Duval, Michel, additional, Teira, Pierre, additional, Therrien, Roxane, additional, Ovetchkine, Philippe, additional, Mallette, Brigitte, additional, and Bittencourt, Henrique, additional

Published
2014
Full Text
View/download PDF

203. Leucemia Mielóide Agura: perfil de duas décadas do Serviço de Hematologia do Hospital das Clínicas de Porto Alegre - RS

Author

Bittencourt, Rosane, Fogliato, Laura, Daudt, Liane, Bittencourt, Henrique N. S., Friederich, João R., Fernandes, Flavo, Onsten, Tor, Fassina, Kátia, Rocha, Luis K. da, Moreno, Fábio, Silva, Geórgia, Cruz, Matheus S., Garcia, Régis G. de, Wasnievski, João C., and Silla, Lúcia M. R.

Subjects
taxa de remissão, Acute Myeloid Leukemia, remission rates, overall survival, sobrevida livre de doença, Leucemia Mielóide Aguda, disease free survival, sobrevida global
Abstract

Nos últimos vinte anos, nosso serviço recebeu os pacientes com a suspeita de Leucemia Mielóide Aguda (LMA) provenientes de todas as regiões do estado. Entre março de 1980 e dezembro de 1999 analisamos 195 pacientes com idades superior a 12 e inferior a 70 anos, apresentando LMA "de novo" excetuando o subtipo M3. Na década de 80 foram registrados 102 pacientes: 47 homens e 55 mulheres. Destes, 84 receberam quimioterapia de indução com Citarabina e Daunorrubicina (esquema "7+3"), resultando no índice de remissão de 51% (43/84). As médias de sobrevidas livre de doença e global foram dez meses em 35% e 12 meses em 13% respectivamente. De jan/90 a dez/93 houve 41 novos diagnósticos e todos foram submetidos à quimioterapia com esquema "7+3" atingindo a taxa de 66% de remissão. As sobrevidas livre de doença e global foram estatisticamente (p

Published
2003

204. Acute myelogenous leukemia : two decades overview - hematology service Hospital de Clínicas de Porto Alegre

Author

Bittencourt, Rosane Isabel, Fogliatto, Laura Maria, Daudt, Liane Esteves, Bittencourt, Henrique Neves da Silva, Friedrisch, Joao Ricardo, Fernandes, Flavo Beno, Silla, Lucia Mariano da Rocha, Onsten, Tor Gunnar Hugo, Fassina, Katia Zanotelli, Wasnievski, João C., Rocha, Luis, Moreno, Fábio de Lima, Garcia, Regis Garcia de, Silva, Georgia Regina S. da, and Cruz, Matheus Silvestri

Subjects
Acute Myeloid Leukemia, Remissão induzida, Protocolos de quimioterapia combinada, Hospital de Clínicas de Porto Alegre. Serviço de Hematologia, Remission rates, Overall survival, Quimioterapia [Leucemia mielocítica aguda], Sobrevivência livre de doença, Disease free survival, Estudos retrospectivos, Taxa de sobrevida
Abstract

Nos últimos vinte anos, nosso serviço recebeu os pacientes com a suspeita de Leucemia Mielóide Aguda (LMA) provenientes de todas as regiões do estado. Entre março de 1980 e dezembro de 1999 analisamos 195 pacientes com idades superior a 12 e inferior a 70 anos, apresentando LMA “de novo” excetuando o subtipo M3. Na década de 80 foram registrados 102 pacientes: 47 homens e 55 mulheres. Destes, 84 receberam quimioterapia de indução com Citarabina e Daunorrubicina (esquema “7+3”), resultando no índice de remissão de 51% (43/84). As médias de sobrevidas livre de doença e global foram dez meses em 35% e 12 meses em 13% respectivamente. De jan/90 a dez/93 houve 41 novos diagnósticos e todos foram submetidos à quimioterapia com esquema “7+3” atingindo a taxa de 66% de remissão. As sobrevidas livre de doença e global foram estatisticamente (p

Published
2003

205. Chemical ecology of Eragrostis planahelps understanding of the species’ invasiveness in an agroecosystem community

Author

von Hertwig Bittencourt, Henrique, Trezzi, Michelangelo Muzell, Teixeira, Sirlei Dias, da Silva Bonome, Lisandro, Garcias de Vargas, Aline, Souza Filho, Antônio da Silva, and Oldoni, Tatiane Cadorin

Abstract

South African lovegrass (Eragrostis plana Nees) is an aggressive and difficult-to-control species in grazing areas of the south of South America, whose invasion capacity is increased by its phytotoxic capability. The objectives of this work were to identify and quantify chemicals produced by the plant shoots, to evaluate the inhibitory capability of plant extracts on development of lucerne (Medicago sativa L.) and wheat (Triticum aestivum L.), and to determine the spatial distribution of phenolics in rhizosphere soil in an infested field. Extracts were obtained by exhaustive extraction of dry shoot biomass, using solvents in increasing order of polarity. Soil samples contained in the rhizosphere were collected from an infested field. Bioassays for determination of phytotoxicity of extracts on lucerne and wheat seedlings were conducted in a completely randomised design with four replicates. The extracts showed suppressive, stimulating or neutral effects on the development of the radicle, shoots, and total lucerne and wheat seedlings, with greater phytotoxicity, generally, of ethyl acetate and methyl alcohol extracts. In the shoot extracts, nine phenolic compounds were identified and quantified: caffeic acid, coumaric acid, ferulic acid, gallic acid, vanillic acid, catechin, epicatechin, resveratrol, rutin. Of these, four were identified in the soil: catechin, epicatechin, coumaric acid, ferulic acid. Catechin, epicatechin and ferulic acid showed similar distribution patterns in the soil profile, with higher concentrations detected on the surface and on the side opposite the plant crown, which indicates release by the decomposition of tissues deposited on the soil surface. Coumaric acid showed higher concentrations on the surface and in the deeper layer of the soil next to the plant, indicating release both from decomposition of the shoots and from the root system. Future work may explore the phytotoxicity of the analytes identified, either isolated or in admixture, using dose curves and an inhibitory response to target plant species.

Published
2018
Full Text
View/download PDF

206. Associação da dose de células CD34 com recuperação hematopoética, infecções e outros desfechos após transplante alogênico de medula óssea de doador familiar HLA-idêntico

Author

Bittencourt, Henrique Neves da Silva and Fuchs, Flávio Danni

Subjects
Resultado do tratamento, Transplante de medula óssea, Coeficiente de mortalidade, Prognóstico, Histocompatibilidade, Transplante homólogo, Transplante de células-tronco hematopoéticas, Contagem de células
Abstract

Resumo não disponível.

Published
2002

207. Potenciais agentes de controle biológico de plantas espontâneas em agroecossistemas no estado do Paraná

Author

von Hertwig Bittencourt, Henrique, Franzener, Gilmar, von Hertwig Bittencourt, Henrique, and Franzener, Gilmar

Abstract

This literature review has as one of the objectives survey the applied biological control agents used in the management of some of the most important weeds species that occur in agroecosystems of the state of Paraná. It has been raised 36 different species that control 5 different species of weeds: beggar-ticks (Bidens pilosa), purple viper's bugloss (Echium plantagineum), arrowleaf sida (Sida rhombifolia), bermudagrass (Cynodon dactylon) and mexican fireplant (Euphorbia heterophylla). Another objective was to report the occurrence of natural biological control of mexican fireplant (E. heterophylla) in soybean fields by ello sphinx (Erinnyis ello), in the Southeast region of the state of Paraná. Despite the lack of records of biological control programs for weeds Brazil has great potential for development in this important field for the expansion of organic agriculture., Esta revisão de literatura teve como um dos objetivos realizar o levantamento de agentes de controle biológico aplicado utilizados no manejo de algumas das principais espécies de plantas espontâneas que ocorrem nos agroecossistemas do estado do Paraná. No total foram levantadas 36 espécies diferentes que controlaram 5 espécies de plantas espontâneas: picão-preto (Bidens pilosa), flor-roxa (Echium plantagineum), guanxuma (Sida rhombifolia), grama-seda (Cynodon dactylon) e leiteiro (Euphorbia heterophylla). Outro objetivo foi registrar a ocorrência de controle biológico natural de leiteiro (E. heterophylla) em lavouras de soja pelo mandarová (Erinnyis ello), na região Sudoeste do Paraná. Apesar da inexistência de registros de programas de controle biológico de plantas espontâneas o Brasil conta com grande potencial para o desenvolvimento de trabalhos nesta área importante para a expansão da agricultura orgânica.

Published
2013

208. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study

Author

Locatelli, Franco, Crotta, Alessandro, Ruggeri, Annalisa, Eapen, Mary, Wagner, John E, Macmillan, Margaret L, Zecca, Marco, Kurtzberg, Joanne, Bonfim, Carmem, Vora, Ajay, Díaz de Heredia, Cristina, Teague, Lochie, Stein, Jerry, O'Brien, Tracey A, Bittencourt, Henrique, Madureira, Adrienne, Strahm, Brigitte, Peters, Christina, Niemeyer, Charlotte, Gluckman, Eliane, Rocha, Vanderson, Locatelli, Franco (ORCID:0000-0002-7976-3654), Locatelli, Franco, Crotta, Alessandro, Ruggeri, Annalisa, Eapen, Mary, Wagner, John E, Macmillan, Margaret L, Zecca, Marco, Kurtzberg, Joanne, Bonfim, Carmem, Vora, Ajay, Díaz de Heredia, Cristina, Teague, Lochie, Stein, Jerry, O'Brien, Tracey A, Bittencourt, Henrique, Madureira, Adrienne, Strahm, Brigitte, Peters, Christina, Niemeyer, Charlotte, Gluckman, Eliane, Rocha, Vanderson, and Locatelli, Franco (ORCID:0000-0002-7976-3654)

Abstract

We retrospectively analyzed 110 patients with juvenile myelomonocytic leukemia, given single-unit, unrelated donor umbilical cord blood transplantation. Median age at diagnosis and at transplantation was 1.4 years (age range, 0.1-6.4 years) and 2.2 years (age range, 0.5-7.4 years), respectively. Before transplantation, 88 patients received chemotherapy; splenectomy was performed in 24 patients. Monosomy of chromosome 7 was the most frequent cytogenetic abnormality, found in 24% of patients. All but 8 patients received myeloablative conditioning; cyclosporine plus steroids was the most common graft-versus-host disease prophylaxis. Sixteen percent of units were HLA-matched with the recipient, whereas 43% and 35% had either 1 or 2 to 3 HLAdisparities, respectively. The median number of nucleated cells infused was 7.1x10(7)/kg (range, 1.7-27.6x10(7)/kg). With a median follow-up of 64 months (range, 14-174 months), the 5-year cumulative incidences of transplantation-related mortality and relapse were 22% and 33%, respectively. The 5-year disease-free survival rate was 44%. In multivariate analysis, factors predicting better disease-free survival were age younger than 1.4 years at diagnosis (hazard ratio [HR], 0.42; P=.005), 0 to 1 HLA disparities in the donor/recipient pair (HR, 0.4; P=.009), and karyotype other than monosomy 7 (HR, 0.5; P=.02). Umbilical cord blood transplantation may cure a relevant proportion of children with juvenile myelomonocytic leukemia. Because disease recurrence remains the major cause of treatment failure, strategies to reduce incidence of relapse are warranted.

Published
2013

209. Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Author

Wolff, Daniel, Cutler, Corey, Lee, Stephanie J., Pusic, Iskra, Bittencourt, Henrique, White, Jennifer, Hamadani, Mehdi, Arai, Sally, Salhotra, Amandeep, Pérez-Simón, Jose A., Alousi, Amin, Choe, Hannah, Kwon, Mi, Bermúdez, Arancha, Kim, Inho, Socié, Gerard, Radojcic, Vedran, O'Toole, Timothy, Tian, Chuan, Ordentlich, Peter, DeFilipp, Zachariah, and Kitko, Carrie L.

Abstract

Background:Chronic graft-versus-host disease (cGVHD) is an immune-mediated complication of allogeneic hematopoietic cell transplant (alloHCT) that affects multiple organs with inflammatory and fibrotic pathology, leading to significant patient burden and mortality. Colony-stimulating factor 1 receptor (CSF-1R)-dependent monocytes and macrophages play a key role in cGVHD inflammation and fibrosis. Axatilimab (SNDX-6352) is an investigational, high-affinity anti-CSF-1R monoclonal antibody that targets monocytes and macrophages. We previously demonstrated the biological and clinical activity of axatilimab with organ-specific responses and symptom improvement in a phase 1/2 study (NCT03604692) in patients with cGVHD.

Published
2023
Full Text
View/download PDF

210. Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study

Author

Gruber, Tanja A., Huang, Minxuan, Jeha, Sima, Deyell, Rebecca J., Lewis, Victor A., Chang, Bill H., Lowe, Eric J., Frediani, Jamie, Vezina, Catherine, Michon, Bruno, Gossai, Nathan, Breese, Erin H., Tran, Thai Hoa, Lacayo, Norman J., Bolen, Christine, Desai, Sunil J., Pauley, Jennifer L., Ashcraft, Emily, Cheng, Cheng, Schultz, Kirk R., Schils, Krysta, Stork, Linda C., Huynh, Van Thu, Richards, Michael, Messinger, Yoav H., Bittencourt, Henrique, Horton, Terzah M., Athale, Uma, Stearns, Duncan, Schiff, Deborah E., and Gaynon, Paul S.

Abstract

Infants with KMT2A rearranged (KMT2Ar) acute lymphoblastic leukemia (ALL) have a poor prognosis with an event-free-survival (EFS) of 33.6-36.9% on recent Children's Oncology Group and Interfant trials. In preclinical studies, we identified bortezomib and vorinostat as novel active agents in primary KMT2Ar infant ALL specimens that have not been included in infant regimens to date. Total therapy for infants with acute lymphoblastic leukemia I (TINI) evaluated this novel combination in a multi-institutional pilot trial for infants with de novoALL. In this study, bortezomib and vorinostat were incorporated into an ALL chemotherapy backbone containing dexamethasone, mitoxantrone, and pegasparaginase during induction and reinduction chemotherapy cycles. A run-in dose escalation evaluated 3 dose levels of vorinostat which was then followed by a dose expansion phase. The primary endpoint of the study was tolerability; secondary endpoints included minimal residual disease (MRD), 3-year EFS and overall survival (OS). Fifty patients enrolled between 2017-2021. Median follow up was 3.4 years (range 1.6-6.8 years). The six patients in the dose escalation phase had no dose-limiting toxicities. Forty-four patients received vorinostat at the third dose level (DL3) of 180 mg/m 2/dose. 68% of patients treated at DL3 had CNS involvement at diagnosis. 68% of DL3 patients carried a KMT2Ar. The most frequent KMT2A partner genes were AFF1 (40%), MLLT1 (20%), and MLLT3 (13%). The most frequent grade 3-4 non-hematologic adverse events during induction include neutropenic fever (45%), hypertension (43%), infection (40%), anorexia (32%), diarrhea (18%) and perineal skin ulceration (16%). There were 3 episodes of sepsis and 1 induction death due to parainfluenza pneumonia. Fewer events and no deaths or proven sepsis occurred during reinduction, with only grade 3 hypertriglyceridemia exceeding 10% of patients affected (18%). 79% of all patients and 69% of KMT2Ar patients became MRD negative by flow cytometry on day 22 of induction following our investigational block. Following induction intensification with cyclophosphamide, cytarabine, and mercaptopurine, 77% and 66% of all patients and KMT2Ar patients respectively were MRD negative at the time of count recovery. Eight of the forty-four patients, all KMT2Ar, underwent stem cell transplant in first remission due to persistent MRD positivity at the end of consolidation.

Published
2023
Full Text
View/download PDF

211. Trends of Obesity over Time and Its Prognostic Significance in Children and Adolescents with Newly-Diagnosed Acute Lymphoblastic Leukemia in Canada: A Population-Based Study

Author

Sassine, Samuel, Pelland-Marcotte, Marie-Claude, Ilinca, André, Athale, Uma, Bittencourt, Henrique, Bowes, Lynette, Brossard, Josée, Israels, Sara J., Donna, Johnston, Kulkarni, Ketan, McKillop, Sarah, Rayar, Meera, Sinha, Roona, Truong, Tony, Vezina, Catherine, Wheaton, Laura, Zorzi, Alexandra, Sung, Lillian, and Tran, Thai Hoa

Abstract

Introduction

Published
2023
Full Text
View/download PDF

212. Efeito de plantas de cobertura de inverno sobre cultivo de milho em sistema de plantio direto.

Author

Bonjorno, Ivan Iuri, Martins, Lauro Artur Otávio, Lana, Marcos Alberto, Bittencourt, Henrique von Hertwig, Wildner, Leandro do Prado, Parizotto, Círio, Fayad, Jamil Abdala, Comin, Jucinei José, Altieri, Miguel Angel, Lovato, Paulo Emílio, Bonjorno, Ivan Iuri, Martins, Lauro Artur Otávio, Lana, Marcos Alberto, Bittencourt, Henrique von Hertwig, Wildner, Leandro do Prado, Parizotto, Círio, Fayad, Jamil Abdala, Comin, Jucinei José, Altieri, Miguel Angel, and Lovato, Paulo Emílio

Abstract

Com o objetivo de avaliar a viabilidade do plantio direto sem herbicidas, foram testadas misturas de centeio, ervilhaca e nabo forrageiro para controle de plantas espontâneas e promoção do rendimento de milho em plantio direto. Mediram-se cobertura do solo e biomassa de plantas de cobertura e espontâneas durante o inverno, rendimento do milho e massa de espontâneas durante o ciclo da cultura de verão. A cobertura do solo durante o período de crescimento das culturas de inverno foi superior a 80%, embora os tratamentos não apresentassem diferenças nas variáveis medidas. As plantas de cobertura proporcionaram boas condições para a cultura comercial, que teve rendimentos entre 6,0 e 6,7 t.ha-1, acima da média da região produtora, sem diferenças entre os tratamentos. Analisando-se valor de grãos colhidos e gastos com sementes das plantas de cobertura, demonstrou-se a viabilidade econômica do plantio direto sem herbicidas para o milho, em sucessão a diferentes coberturas de inverno.

Published
2010

213. Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation

Author

Ansari, Marc, primary, Théoret, Yves, additional, Rezgui, Mohamed Aziz, additional, Peters, Christina, additional, Mezziani, Samira, additional, Desjean, Catherine, additional, Vachon, Marie-France, additional, Champagne, Martin A., additional, Duval, Michel, additional, Krajinovic, Maja, additional, and Bittencourt, Henrique, additional

Published
2014
Full Text
View/download PDF

214. Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients

Author

Kurtzberg, Joanne, primary, Prockop, Susan, additional, Teira, Pierre, additional, Bittencourt, Henrique, additional, Lewis, Victor, additional, Chan, Ka Wah, additional, Horn, Biljana, additional, Yu, Lolie, additional, Talano, Julie-An, additional, Nemecek, Eneida, additional, Mills, Charles R., additional, and Chaudhury, Sonali, additional

Published
2014
Full Text
View/download PDF

215. Uso de fatores de crescimento hematopoieticos em pacientes portadores de leucemias agudas, recaidas ou refratarias submetidos a quimioterapia de altas doses

Author

Bittencourt, Henrique Neves da Silva and Fuchs, Flávio Danni

Subjects
Efeitos adversos [Quimioterapia], Etiologia [Neutropenia], Complicações [Leucemia], Hematínicos
Abstract

MARCO TEÓRICO A neutropenia é freqüente nos pacientes submetidos a quimioterapia e predispõe a um aumento na incidência de episódios infecciosos. A duração e intensidade do período de neutropenia estão diretamente relacionados à intensidade da quimioterapia administrada. A disponibilidade dos fatores de crescimento hematopoiéticos da linhagem mielóide, G-CSF e GM-CSF, constituíram-se em nova abordagem para reduzir o período de neutropenia e, presumivelmente, as complicações infecciosas. Não há consenso sobre a real utilidade do emprego de fatores de crescimento como terapia ad.iuvante em pacientes com leucemias agudas. Ensaios clínicos envolvendo leucemias agudas recaídas ou refratárias são raros e mostraram resultados similares aos obtidos nas leucemias agudas "de novo", ou seja, redução no período de neutropenia sem repercussão na taxa de óbito ou remissão. OBJETIVOS Principal: avaliar o efeito dos fa tores de crescimento sobre a mortalidade hospitalar dos portadores de leucemias agudas recaídas ou refratárias submetidos a quimioterapia ele alta- dose. Secundários: avaliar o impacto do uso destes fatores sobre o gasto com antibióticos, dias ele neutmpenia, dias de internação, dias de febre, incidência de infecções e taxa de remissão. CONCLUSÃO O emprego de fatores de crescimento, em pacientes com leucemia aguda recaída atendidos na clínica hematológica do Hospital de Clínicas de Porto Alegre, não modificou a taxa de mortalidade, a freqüência de remissão e outros parâmetros clínicos de interesse. BACKGROUND Neutropenia is a common feature in patients treated with chemotherapy and is associated with an increased incidence of infections. The duration and intensity of neutropenia are mainly determin ated by the intensity of the chemotherapy regimen. Availability of recombinant myeloid growth factors (G-CSF and GM-CSF) brought up a new approach to reduce the duration of neutropenia and presumably, the incidence of infections. There i no consensus on the value of use of growth factors as adjuvant therapy in patients with acute leukemias. There is a few clinicai trials with patients 1..vith relapsed acute leukemias, and despire showing a reduction in the duration of neutropenia, they do not show reduction in the death or remission rates. ÜBJECTIVES Principal: to evaluate the effect of growth factors in the mortaliry rate of patients treatt!d with high-dose chemotherapy for relapsed acute leukemia. Secondary: to evaluate the effect of use of hematopoietic growth factors on the costs of antibiotic use, days of neutropenia, fever, lenght of hospitali:ation, and remission rares. CONCLUSION The use of hematopoietic growth factors in patients with relapsed acute leukenúa treated in the hematological clliúcs of the Hospital de Clfnicas de Porto Alegre did not modify the mortality rate, frequency of renússion and other clinicai parameters.

Published
1998

217. Sulfolane (a metabolite of busulfan) Levels Could Predict Occurrence Of Hemorrhagic Cystitis In Children Receiving Busulfan Based Myeloablative Conditioning Before Hematopoietic Stem Cell Transplantation

Author

Uppugunduri, Chakradhara Rao S, primary, Rezgui, Mohamed Aziz, additional, Theoret, Yves, additional, Diaz, Patricia Huezo, additional, Tyagi, Anuj Kumar, additional, Mezziani, Samira, additional, Vachon, Marie-France, additional, Desjean, Catherine, additional, Duval, Michel, additional, Bittencourt, Henrique, additional, Krajinovic, Maja, additional, and Ansari, Marc, additional

Published
2013
Full Text
View/download PDF

219. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study

Author

Locatelli, Franco, primary, Crotta, Alessandro, additional, Ruggeri, Annalisa, additional, Eapen, Mary, additional, Wagner, John E., additional, MacMillan, Margaret L., additional, Zecca, Marco, additional, Kurtzberg, Joanne, additional, Bonfim, Carmem, additional, Vora, Ajay, additional, Díaz de Heredia, Cristina, additional, Teague, Lochie, additional, Stein, Jerry, additional, O’Brien, Tracey A., additional, Bittencourt, Henrique, additional, Madureira, Adrienne, additional, Strahm, Brigitte, additional, Peters, Christina, additional, Niemeyer, Charlotte, additional, Gluckman, Eliane, additional, and Rocha, Vanderson, additional

Published
2013
Full Text
View/download PDF

220. The Clinical Relevance of Pre-Formed Anti-HLA and Anti-MICA Antibodies after Cord Blood Transplantation in Children

Author

Ansari, Marc, primary, Uppugunduri, Chakradhara Rao S., additional, Ferrari-Lacraz, Sylvie, additional, Bittencourt, Henrique, additional, Gumy-Pause, Fabienne, additional, Chalandon, Yves, additional, Tiercy, Jean-Marie, additional, Schechter, Tal, additional, Gassas, Adam, additional, Doyle, John D., additional, Dupuis, Lee, additional, Duval, Michel, additional, Krajinovic, Maja, additional, and Villard, Jean, additional

Published
2013
Full Text
View/download PDF

223. Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?

Author

Ruggeri, Annalisa, primary, Bittencourt, Henrique, additional, Sanz, Guillermo, additional, Rambaldi, Alessandro, additional, Yakoub-Agha, Ibrahim, additional, Ribeira, Josep-Maria, additional, Arcese, William, additional, Mannone, Lionel, additional, Sierra, Jorge, additional, Solano, Carlos, additional, Nabhan, Samir, additional, Tucunduva, Luciana, additional, Volt, Fernanda, additional, Kenzey, Chantal, additional, Gluckman, Eliane, additional, Labopin, Myriam, additional, and Rocha, Vanderson, additional

Published
2013
Full Text
View/download PDF

225. Association Between Busulfan First-Dose Pharmacokinetics and Outcome in Children Receiving Myeloablative Busulfan-Based Conditioning Before Unrelated Umbilical Cord Blood Transplantation for Malignancies

Author

Bittencourt, Henrique, primary, Rezgui, Mohamed Aziz, additional, Meziani, Samira, additional, Vachon, Marie-France, additional, Desjean, Catherine, additional, Duval, Michel, additional, Theoret, Yves, additional, Krajinovic, Maja, additional, and Ansari, Marc, additional

Published
2012
Full Text
View/download PDF

226. Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?.

Author

Ruggeri, Annalisa, primary, Bittencourt, Henrique, additional, Sanz, Guillermo, additional, Rambaldi, Alessandro, additional, Yakoub-Agha, Ibrahim, additional, Ribera, Josep-Maria, additional, Arcese, William, additional, Mannone, Lionel, additional, Sierra, J., additional, Solano, Carlos, additional, Nabhan, Samir Kanaan, additional, Tucunduva, Luciana, additional, Volt, Fernanda, additional, Kenzey, Chantal, additional, Gluckman, Eliane, additional, Labopin, Myriam, additional, and Rocha, Vanderson, additional

Published
2012
Full Text
View/download PDF

227. Association of Cth Genetic Variant with Veno-Occlusive Disease in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation.

Author

Huezo-Diaz, Patricia, primary, Uppungunduri, Chakradhara Rao, additional, Tyagi, Anuj Kumar, additional, Rezgui, Mohamed Aziz, additional, Gumy-Pause, Fabienne, additional, Duval, Michel, additional, Bittencourt, Henrique, additional, Krajinovic, Maja, additional, and Ansari, Marc, additional

Published
2012
Full Text
View/download PDF

229. Posaconazole Plasma Monitoring in Immunocompromised Children.

Author

McMahon, Jessica, Théorêt, Yves, Autmizguine, Julie, Bittencourt, Henrique, Tapiéro, Bruce, and Ovetchkine, Philippe

Abstract

Plasma posaconazole exposure was assessed in 13 children who underwent a hematopoietic stem cell transplant. The median dosage was 12.5 mg/kg per day, divided into 3 doses. Of these 13 patients, 46.2% (6) and 30.8% (4) achieved concentrations higher than 0.7 and 1.25 mg/L, respectively. In children at high risk, a higher dosage might be needed to achieve target concentrations.

Published
2017
Full Text
View/download PDF

230. Myeloablative Conditioning with Pharmacokinetic-Targeted Intravenous Busulfan and Cyclophosphamide in Unrelated Cord Blood Transplantation for Myeloid Malignancies in Children

Author

Bittencourt, Henrique, primary, Ansari, Marc, additional, Rezgui, Mohamed Aziz, additional, Meziani, Samira, additional, Vachon, Marie-France, additional, Desjean, Catherine, additional, Duval, Michel, additional, Théoret, Yves, additional, and Krajinovic, Maja, additional

Published
2011
Full Text
View/download PDF

231. Influence of Cytogenetic, Molecular Abnormalities and Other Risk Factors on the Outcomes of Children with Acute Myelogenous Leukemia Given An Unrelated Cord Blood Transplantation. A Survey on Behalf of Eurocord, ALWP and PDWP of EBMT

Author

Cunha, Renato, primary, Michel, Gerard, additional, O'Brien, Tracey, additional, de Souza, Mair Pedro, additional, Bittencourt, Henrique, additional, Socié, Gérard, additional, Bordigoni, Pierre, additional, Locatelli, Franco, additional, Ayas, Mouhab, additional, Iori, Anna Paola, additional, Vora, Ajay J, additional, Dalle, Jean-Hugues, additional, Toledo, José Sanches, additional, Ruggeri, Annalisa, additional, Mohty, Mohamad, additional, Peters, Christina, additional, Gluckman, Eliane, additional, and Rocha, Vanderson, additional

Published
2011
Full Text
View/download PDF

235. The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia

Author

Marcolino, Milena Soriano, primary, Ribeiro, Antonio Luiz, additional, Clementino, Nelma C.D., additional, Nunes, Maria do Carmo P., additional, Barbosa, Márcia M., additional, Silva, Maria Helena C.R., additional, Bittencourt, Henrique N.S., additional, Geleijnse, Marcel L., additional, and Boersma, Eric, additional

Published
2011
Full Text
View/download PDF

236. Quantification of CD8+CD38+ T lymphocytes by flow cytometry does not represent a good biomarker to monitor the reactivation of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

Author

Lino, Vânia Abadia Soares, primary, Santos, Silvana Maria Eloi, additional, Bittencourt, Henrique Neves da Silva, additional, Silva, Maria Luiza, additional, Spizziri, Tiago, additional, Bretas, Raquel, additional, and Neves, Suzane Pretti Figueiredo, additional

Published
2011
Full Text
View/download PDF

238. Analysis of Risk Factors Influencing Outcomes After Unrelated Cord Blood Transplantation In Children with Juvenile Myelomonocytic Leukemia. An Eurocord, EBMT, EWOG-MDS, CIBMTR Study

Author

Crotta, Alessandro, primary, Rocha, Vanderson, additional, Eapen, Mary, additional, Wagner, John E., additional, MacMillan, Margaret L., additional, Zecca, Marco, additional, Kurtzberg, Joanne, additional, Bonfim, Carmen, additional, Vora, Ajay J., additional, de Heredia, Cristina Díaz, additional, Mohty, Mohamad, additional, Teague, Lochie, additional, Stein, Jerry, additional, O'Brien, Tracey A., additional, Bittencourt, Henrique, additional, Madureira, Adrienne B.M., additional, Peters, Christina, additional, Niemeyer, Charlotte Marie, additional, Gluckman, Eliane, additional, and Locatelli, Franco, additional

Published
2010
Full Text
View/download PDF

242. Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using Alemtuzumab and Cyclophosphamide as Conditioning Regimen.

Author

Lodi, Fernanda, primary, Teixeira, Gustavo, additional, Macedo, Antonio Vaz, additional, Lamego, Rosana, additional, Magalhaes, Simone Silva, additional, Tiburcio, Ana Flavia, additional, Santoro, Ana Luiza, additional, Gomes, Rodrigo, additional, Vieira, Ana Karine, additional, Xavier, Sandra, additional, and Bittencourt, Henrique, additional

Published
2009
Full Text
View/download PDF

243. Unrelated Cord Blood Transplantation in Patients with Hematologic Malignancies in Brazil – A Sociedade Brasileira De Transplantes De Medula Ossea and Eurocord Collaborative Study.

Author

Rodrigues, Celso Arrais, primary, Setubal, Daniela, additional, Bonfim, Carmem, additional, Nabhan, Samir Kanaan, additional, Colturato, Vergílio Antônio Renzi, additional, Mauad, Marcos Augusto, additional, de Souza, Mair Pedro, additional, de Azevedo, Alexandre Mello, additional, Hamerschlak, Nelson, additional, Seber, Adriana, additional, Bittencourt, Henrique, additional, Gonçalves, Matheus Vescovi, additional, de Castro, Claudio Galvao, additional, Dulley, Frederico L., additional, De Souza, Carmino Antonio, additional, Chaves, Wagnara, additional, Neto, Jose Zanis, additional, Pasquini, Ricardo, additional, Gluckman, Eliane, additional, Rocha, Vanderson, additional, and Bouzas, Luis Fernando, additional

Published
2009
Full Text
View/download PDF

245. Correction to: GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation.

Author

Jurkovic Mlakar, Simona, Uppugunduri, Satyanarayana Chakradhara Rao, Nava, Tiago, Mlakar, Vid, Golay, Hadrien, Robin, Shannon, Waespe, Nicolas, Rezgui, Mohamed Aziz, Chalandon, Yves, Boelens, Jaap Jan, Bredius, Robert G. M., Dalle, Jean-Hugues, Peters, Christina, Corbacioglu, Selim, Bittencourt, Henrique, Krajinovic, Maja, and Ansari, Marc

Subjects
HEMATOPOIETIC stem cell transplantation, HEMATOLOGIC malignancies, CELL proliferation
Published
2022
Full Text
View/download PDF

246. An evaluation of the cardiotoxicity of imatinib mesylate

Author

Ribeiro, Antonio Luiz, primary, Marcolino, Milena Soriano, additional, Bittencourt, Henrique N.S., additional, Barbosa, Márcia M., additional, Nunes, Maria do Carmo P., additional, Xavier, Vitor Fonseca, additional, and Clementino, Nelma C.D., additional

Published
2008
Full Text
View/download PDF

248. Mutant TIRAP Gene Polymorphism Is Associated with Outcomes in HLA Genoidentical Bone Marrow Transplants Recipients with Leukemia.

Author

Rocha, Vanderson, primary, Porcher, Raphael, additional, Kabbara, Nabil, additional, de Latour, Regis Peffault, additional, Robin, Marie, additional, Chaves, Wagnara, additional, Rodrigues, Celso A., additional, Bittencourt, Henrique, additional, Tavela, Marli, additional, Devergie, Agnes, additional, Ribaud, Patricia, additional, Gluckman, Eliane, additional, Socie, Gerard, additional, and Zago, Marco Antonio, additional

Published
2007
Full Text
View/download PDF

249. Imatinib Mesilate Versus Allogeneic Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia in First Chronic Phase - A Brazilian Point of View.

Author

Bittencourt, Henrique, primary, Funke, Vaneuza, additional, Fogliatto, Laura, additional, Magalhaes, Simone, additional, Setubal, Daniela, additional, Paz, Alessandra, additional, Macedo, Antonio V., additional, Ruiz, Jefferson, additional, Azambuja, Ana Paula, additional, Silla, Lucia M.R., additional, Clementino, Nelma, additional, and Pasquini, Ricardo, additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results